ChexTSEH2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ChexTSEH2
• 英文别名: 1-(4-chlorophenyl)-3-[(E)-[(2E)-2-[(4-chlorophenyl)carbamothioylhydrazinylidene]ethylidene]amino]thiourea
• 化学式: C₁₆H₁₄Cl₂N₆S₂
• 分子量: 425.365
• InChiKey: XQIKNESFTSDFBC-LQGKIZFRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  137
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ChexTSEH2 、 copper diacetate 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以71%的产率得到copper;N'-[(E)-[(2E)-2-[(Z)-[(4-chloroanilino)-sulfidomethylidene]hydrazinylidene]ethylidene]amino]-N-(4-chlorophenyl)carbamimidothioate
  参考文献：
  名称：

  WO2008/61306

  摘要：

  公开号：
• 作为产物：
  描述：

  4-(4-氯苯)-3-氨基硫脲 在 草酸醛 作用下， 以 1,4-二氧六环 、 水 、 溶剂黄146 为溶剂， 反应 2.0h， 以71%的产率得到ChexTSEH2
  参考文献：
  名称：

  WO2008/61306

  摘要：

  公开号：

文献信息

• Metal delivery agents and terapeutic uses of the same
  申请人：The University of Melbourne

  公开号：EP2813223A1

  公开（公告）日：2014-12-17

  The present invention relates to metal complexes, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of conditions in which metal delivery can prevent, alleviate or ameliorate the condition. There are a number of clinical conditions which are caused by or associated with abnormal levels of metals (typically low metal levels). Conditions in of this type include cancer and conditions characterised by or associated with oxidative damage, more specifically neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease or Huntingdon's disease. The invention also relates to ligands useful in the preparation of metal complexes of this type.

  本发明涉及金属络合物、其制备工艺及其作为药物或兽药的用途，特别是用于治疗给药金属可预防、减轻或改善病情的情况。有许多临床症状是由金属含量异常（通常是金属含量过低）引起或与之相关。这类疾病包括癌症和以氧化损伤为特征或与之相关的疾病，更具体地说是神经退行性疾病，如阿尔茨海默病、帕金森病或亨廷顿氏病。本发明还涉及用于制备这类金属复合物的配体。
• METAL DELIVERY AGENTS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
  申请人：The University of Melbourne

  公开号：EP3238719A1

  公开（公告）日：2017-11-01

  The present invention relates to metal complexes for use as pharmaceutical or veterinary agents for the treatment of multiple sclerosis. There are a number of clinical conditions which are caused by or associated with abnormal levels of metals (typically low metal levels). Conditions of this type include multiple sclerosis. The invention also relates to ligands useful in the preparation of metal complexes of this type.

  本发明涉及用作治疗多发性硬化症的药物或兽药的金属复合物。有许多临床病症是由金属含量异常（通常是低金属含量）引起或与之相关。这类疾病包括多发性硬化症。本发明还涉及用于制备此类金属配合物的配体。
• Metal delivery agents and therapeutic uses of the same
  申请人：THE UNIVERSITY OF MELBOURNE

  公开号：US10413554B2

  公开（公告）日：2019-09-17

  The present invention relates to metal complexes, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of conditions in which metal delivery can prevent, alleviate or ameliorate the condition. There are a number of clinical conditions which are caused by or associated with abnormal levels of metals (typically low metal levels). Conditions in of this type include cancer and conditions characterized by or associated with oxidative damage, more specifically neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease or Huntington's disease. The invention also relates to ligands useful in the preparation of metal complexes of this type.

  本发明涉及金属络合物、其制备工艺及其作为药物或兽药的用途，特别是用于治疗给药金属可预防、减轻或改善病情的情况。有许多临床症状是由金属含量异常（通常是金属含量过低）引起或与之相关。这类疾病包括癌症和以氧化损伤为特征或与之相关的疾病，更具体地说是神经退行性疾病，如阿尔茨海默病、帕金森病或亨廷顿病。本发明还涉及用于制备这类金属复合物的配体。
• METAL COMPLEXES AND METHODS OF TREATMENT
  申请人：Collaborative Medicinal Development, LLC

  公开号：EP3068762B1

  公开（公告）日：2019-12-25
• METAL DELIVERY AGENTS AND THERAPEUTIC USES OF THE SAME
  申请人：Barnham Kevin Jeffrey

  公开号：US20120270850A1

  公开（公告）日：2012-10-25

  The present invention relates to metal complexes, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of conditions in which metal delivery can prevent, alleviate or ameliorate the condition. There are a number of clinical conditions which are caused by or associated with abnormal levels of metals (typically low metal levels). Conditions in of this type include cancer and conditions characterised by or associated with oxidative damage, more specifically neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease or Huntington's disease. The invention also relates to ligands useful in the preparation of metal complexes of this type.